版本:
中国

BRIEF-Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in Phase 3 summit-07 study in chronic pain

March 20 Nektar Therapeutics

* Nektar Therapeutics says NKTR-181, an opioid analgesic, meets primary and secondary endpoints in phase 3 summit-07 study in chronic pain

* Nektar therapeutics says NKTR-181 significantly reduced pain in patients with moderate to severe chronic low back pain

* FDA has granted investigational NKTR-181 fast track designation for the treatment of moderate to severe chronic pain Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐